MBX Biosciences, Inc. (MBX)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Steven L. Hoerter
|
Executive Chairperson, CEO & President | 40.48k | -- | 1971 |
|
Dr. Salomon Azoulay M.D.
|
Chief Medical Officer | 734.94k | -- | 1958 |
|
Mr. John W. Smither CPA
|
Chief Financial Officer | -- | -- | 1953 |
|
Mr. Pete De Spain
|
Senior Vice President of Investor Relations & Corporate Communications | -- | -- | -- |
|
Mr. Jeffrey Held J.D.
|
Chief Legal Officer | -- | -- | 1969 |
|
Ms. Michelle Graham
|
Chief Human Resources Officer | -- | -- | 1967 |
|
Dr. Michael A. Dorato DABT, Ph.D.
|
Sr. Vice President of Discovery & Non-Clinical Development | -- | -- | -- |
|
Dr. Chatan Charan Ph.D.
|
Senior VP of Pharmaceutical Development & Chemistry, Manufacturing and Controls | -- | -- | -- |
|
Mr. Mark Hope
|
Chief Regulatory & Quality Officer | -- | -- | -- |
|
Dr. Andreas Moraitis M.D.
|
Senior Vice President of Clinical Development | -- | -- | -- |
MBX Biosciences, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 63
Description
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Corporate Governance
Upcoming Events
November 5, 2026 at 1:30 PM UTC
MBX Biosciences, Inc. Earnings Date
